Home Cart Sign in  
Chemical Structure| 20633-67-4 Chemical Structure| 20633-67-4

Structure of Calycosin-7-O-β-D-glucoside
CAS No.: 20633-67-4

Chemical Structure| 20633-67-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Calycosin-7-O-β-D-glucoside is an isoflavone isolated from Astragalus membranaceus. It possesses various biological activities including neuroprotection, cardioprotection, anti-inflammatory, and antioxidant effects.

Synonyms: Calycosin-7-glucoside; Calycosin-7-O-beta-D-glucoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Calycosin-7-O-β-D-glucoside

CAS No. :20633-67-4
Formula : C22H22O10
M.W : 446.40
SMILES Code : O=C1C(C2=CC=C(OC)C(O)=C2)=COC3=C1C=CC(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C3
Synonyms :
Calycosin-7-glucoside; Calycosin-7-O-beta-D-glucoside
MDL No. :MFCD08061493
InChI Key :WACBUPFEGWUGPB-MIUGBVLSSA-N
Pubchem ID :5318267

Safety of Calycosin-7-O-β-D-glucoside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human mesenchymal stem cells 1-10 μM 21 days Evaluate late osteogenic differentiation, results showed that Caly promoted the formation of mineralized nodules PMC8583672
Human mesenchymal stem cells 1-10 μM 24 hours Evaluate cell migration ability, results showed that Caly significantly promoted the migration of MSCs PMC8583672
NHBE cells 1000 µg/ml and 500 µg/ml 24 hours To evaluate the effect of AR on CSE-induced autophagy in NHBE cells, results showed that AR significantly reduced the number of autophagosomes and autolysosomes and increased cellular structural integrity. PMC7898675
HT22 cells 35, 70, 140 μM 24 hours To investigate the protective effect of CAG on OGD/R-injured HT22 cells and its potential mechanism. Results showed that CAG significantly reduced ROS levels, apoptosis rate, and improved cell viability. PMC11819903
B16F10 cells 1–1000 µg/mL 48 hours To evaluate the effect of YQD on melanogenesis in B16F10 cells. Results showed that YQD increased melanin content in B16F10 cells in a dose-dependent manner, significantly enhanced cellular tyrosinase activity, and upregulated TRP-1 gene and protein expression. PMC10747336
Mouse liver microsomes 100 ng/mL 60 minutes To study the effect of CYP450 enzyme-specific inhibitors on the metabolism of Calycosin-7-O-β-D-glucoside, results showed no significant effect. PMC10146250
Human mesenchymal stem cells 1-10 μM 7 days Evaluate early osteogenic differentiation, results showed that Caly increased ALP expression and activity PMC8583672

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley (SD) rats Rheumatoid arthritis model Oral gavage 0.648 g/100g/d 7 consecutive days To evaluate the therapeutic effect of Xinfeng Capsule on rheumatoid arthritis. Results showed that Xinfeng Capsule significantly improved joint histopathological damage, inhibited NF-κB pathway activation, and promoted synovial cell apoptosis. PMC11966437
Mice Diabetic nephropathy model Oral 0.96 g/kg, 0.48 g/kg, and 0.24 g/kg Once daily for 12 weeks To investigate the effects of HQD on diabetic nephropathy and the tissue distribution difference of its active constituents between normal and diabetic nephropathy mouse models. Results showed that HQD significantly decreased fasting blood glucose, 24-h urinary protein, blood urea nitrogen, serum creatinine, and triglyceride levels in DN mice. PMC9253459
Sprague-Dawley rats Normal rat model Oral 10 mg/mL Single dose, duration of 720 minutes To evaluate the effect of APS on the pharmacokinetics of CAG, results showed that APS significantly increased the maximum concentration (Cmax) and area under the curve (AUC) of CAG. PMC10656867
Zebrafish Zebrafish embryos Aqueous exposure 200–1200 µg/mL Continuous exposure from 24 hpf to 84 hpf To evaluate the effect of YQD on melanogenesis in zebrafish. Results showed that YQD significantly promoted melanin production in zebrafish, especially at concentrations of 400–1200 μg/mL, where melanin density was significantly higher than in the control group. PMC10747336
A/J mice Lung cancer model Oral 5.2 g/kg/d and 2.6 g/kg/d Once daily for 28 weeks To evaluate the therapeutic effect of AR on the lung cancer model, results showed that AR significantly reduced the number of lung tumor nodules, improved lung tissue structural integrity, and inhibited autophagy by upregulating p53 expression and downregulating p-Bcl-2 expression. PMC7898675

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.24mL

0.45mL

0.22mL

11.20mL

2.24mL

1.12mL

22.40mL

4.48mL

2.24mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories